“Thank you for your interest in the company. We are a global advisory firm specializing in cross-border deal flow focused in China’s healthcare industry. The firm is the leading platform to facilitate partnerships to fuse Chinese capital, its large and fast-growing market with US/EU healthcare innovation.

With an experienced team of well-connected industry veterans from all over the world and the largest network in China’s healthcare industry, TPP has become the market expert with the top-notch network to execute and support cross-border transactions involving pharmaceuticals, medical devices and diagnostics.”

Tony Chu, Co-Founder + Managing Partner of TPP Healthcare

TPP Management

Tony Chu
Co-Founder / Managing Partner
With over 20 years of cross-border transaction experience in US/EU and Chinese chemical and pharmaceutical industries, Chu is the Founder and Managing Partner of TPP. He also sits as a Board Member for several companies including Eastar Chemical Corp, Pharma Partners Snd Bhd (Malaysia) and PT Inodia (Indonesia).
Asa Cox
Co-Founder / Partner
Cox is a Founding Partner of TPP. With over 20 years of healthcare licensing and business development experience, he has been globally connected since 1997 with a network of over 20,000 companies. Cox also serves as the Founder & CEO of Generic Pharma 2.0 and Chairman of GenericLicensing.com.
James Bruno
Bruno is a Partner at TPP with 40+ years of Senior Executive experience, most notably with Honewell, Viachem, Aeroject and Sipsy. Previously, he was the Former President of the Drug, Chemical & Allied Technologies Association (DCAT) – the largest and oldest pharmaceutical association in the world.
Mohd Zul Efendi
Partner for Malaysia
Efendi is a Partner at TPP, based in Malaysia. There he boosts 15 years of experience in the ASEAN healthcare industry and recently sat as Senior Manager and Head of Business Development at Pharmaniaga Berhad and BD Director at Biosis Group Berhad.
Ramlan Ibrahim
Partner for Malaysia
Ibrahim is a Partner at TPP, based in Malaysia. With 20 years of experience in pharmaceutical and healthcare in the ASEAN market, he was recently Senior General Manager of Global Sales & Marketing at Pharmaniaga.
Guang Yu
With over 15 years of business development experience, Guang possesses strong knowledge in government regulation and reimbursement. Previously, he is former Executive Director of several large Chinese pharma companies specializing in building relationships with government regulatory authorities and insurance reimbursement.


Jackie Cha
Director of Research
Cha serves TPP as Director of Research, with a focus on China healthcare market intelligence. With over 12 years of healthcare consulting experience, she has deep expertise in supporting transactions of sorts in healthcare space. Previously, Cha held a senior executive role at a China-based healthcare consulting practice.
Angela Byrne
Director of Corporate Communications
With nearly a decade of Corporate Communications experience, through the Financial Services and Healthcare sectors, Byrne serves TPP as Head of Communications, both internally and externally. Previously, she held a managerial role at an international communications agency and currently sits on the Board for the American Cancer Society’s Distinguished Events Committee. Byrne holds a Masters of Corporate Communications, with a focus in Public Relations.
Trisha Salerno
Director of Events
Salerno serves TPP as Director of Events, bringing more than a decade of experience conceptualizing, planning, promoting, managing and executing high profile, large scale events – ranging in format and geographical locations, with the goal of heightening participant satisfaction and elevating brand awareness. Prior to joining the TPP team, Salerno served as Senior Manager of Distinguished Events for the American Cancer Society and spent six years working for the Breast Cancer Research Foundation (BCRF) as the Associate Director of Development and Events.
Nat Whitney
Managing Director
With 20+ years of healthcare experience in China and the U.S., Whitney serves TPP as Managing Director with a focus on China IVD market. Whitney has an ardent interest in Healthcare reform, having investigated the China healthcare system for the Bill and Melinda Gates Foundation in 2007. He also serves as President of Whitney Research, a strategic affiliate of TPP which specializes in market research of Chinese IVD market.

Venture Partners

Amiram Katzman
Venture Partner
Katzman is a Venture Partner of TPP. With 10+ years of experience in business development, he successfully connects clients with foreign markets and helps leverage their access to quality M&A and investment prospects. He currently serves Prodan Networks as CEO of the company.
Shizhong Luo
Venture Partner
Mr. Luo has 20 years of experience managing cross border project, licensing and manufacturing between multnational national companies and Chinese enterprises. He held head of BD Positions at Yabao Pharmaceuticals, Xinhua Pharmceuticals and Board Secretary of JV between Xinhua and Perrigo. He is graduate of Peking University (Master of International Pharmceutical Engineer Management).
Xiao Shu, PhD
Venture Partner
Shu is a Venture Partner for TPP. Currently, Shu sits as the Managing Partner at Guijing Capital and owns 12 years of healthcare investment experience. Previously, he was the Former Portfolio Manager at Kangjing Capital, a healthcare Venture Capital. He graduated from University of California, Berkeley with a PhD degree in Metabolic Biology.


Harvey Fine
Fine is an Advisor to the cross-border and emerging market private equity group at TPP. His expertise spans strategic partnerships/business development and M&A transactions with emphasis on China and India cross-border deals with the US and Europe. He also serves Fosun Group as the Managing Director in US-Global Investments & Strategies.
Justin Heyl

Justin Heyl, Advisory and Cybersecurity Business Development Director, for UL – Justin is responsible for the management of UL LLC’s suite of services to support global regulatory approvals for medical device companies. He joined UL as the Global Account Director responsible for Boston Scientific, Medtronic, St. Jude and supporting the global accounts team with medical related compliance services. Prior to joining UL, he was the program manager for Intertek’s consulting services, worked as an orthopedic sales representative for Primary Surgical and a mechanical engineer for Crane Engineering and Forensic Services. He has partnered with medical device companies throughout the product development cycle and certification to expedite market access on a global scale. He has successfully managed projects and international submissions with start-ups, VC backed companies as well as many of the top 10 medical companies in the world.  Justin holds a Bachelor of Science degree in Mechanical Engineering from the University of Minnesota and has over twenty-two years of industry experience focusing on medical regulatory solutions and business development with medical companies.

Lefei Sun
Lefei currently serves as Founding Partner of HuaTai Healthcare Investment Fund. With more than 10 years of experience in healthcare analysis and M&A, he possesses strong knowledge in healthcare PE/VC investments in Greater China regions and cross-border deals, and supports global SME healthcare company in China market development.
Xielong Luo
With over 30 years of experience in the Chinese healthcare industry, Mr Luo also currently holds these position: Vice Chairman of CPEA and head of its international steering committee; Vice Chair of China OTC Association; Director of Yangtze River Delta Biological Medicine Research and Development Center of Zhejiang Province. His previous roles include: Director of the Medical Administration on Department of Hangzhou Board of Health, Chairman of National Medicine Research and Development Center; President of Chinese Academy of Sciences of Beijing General Pharmaceutical Corporation; VP of Beijing General Pharmaceutical Corporation, GM of Hangzhou Biological Medicine Industry investment Corporation. His advisory roles include China Medical Representative Office of the United Nations Industrial Development Organization (UNIDO), China’s “11th five-year plan” and “12th five-year plan” of Chinese Biological Medicine.
Alex Xu
Alex has over 20 years experience in China as Surgeon and executive management positions including Country Manager of CR Bard. Alex currently is Managing Partner of China Medtech Commercialization Fund 1 (CMC1). Chairman/CEO of Beijing GMT, an oncology focused diagnostic and device company in China.
Pei Zhou
Pei is currently Partner of China Medtech Commercialization Fund 1 (CMC 1); Co-head of Pagoda Capital Healthcare. With more than 15 years of research and investment experience in the healthcare industry. Previously, Dr. Zhou served as a Senior Associate of China Everbright Limited Healthcare Investment Fund and has a vast reputation for sourcing, evaluating and the execution of equity investments in Pharmaceutical, medtech and healthcare services sub-sectors.
Ivan Lo
With over 20 years senior executive experience in transnational pharmaceutical companies covering government affairs, finance, product registration and sales, etc. Ivan’s previous roles include Finance Director of Novartis China; Director of Operations at Wyeth China; and Finance Director of Nutricia in charge of operations and its pediatric nutrition department.

Strategic Alliances

Note: Partial List